Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20428739 | 0.83 | CCR1 (0.42) | IKBKETBK1SUV39H2BTK | |
| SCHEMBL25198156 | 0.83 | HDAC4 (0.35) | IKBKETBK1SUV39H2BTK | |
| SCHEMBL25224516 | 0.80 | NPSR1 (0.36) | IKBKETBK1SUV39H2BTK | |
| SCHEMBL629835 | 0.79 | PIK3CD (0.36) | IKBKETBK1SUV39H2BTK | |
| SCHEMBL3542327 | 0.78 | CYP1A2 (0.39) | SUV39H2 | |
| SCHEMBL4480745 | 0.77 | SPR (0.43) | SUV39H2BTK | |
| SCHEMBL746391 | 0.77 | KDM4E (0.38) | IKBKETBK1SUV39H2BTK | |
| SCHEMBL6269678 | 0.76 | P4HTM (0.40) | — | |
| SCHEMBL16680799 | 0.75 | PIK3CA (0.37) | IKBKETBK1SUV39H2BTK | |
| SCHEMBL25547740 | 0.75 | TDP1 (0.52) | IKBKETBK1SUV39H2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2862856-A1 | AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | IKBKE 986/4885TBK1 3754/4885SUV39H2 321/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | IKBKE 986/4885TBK1 3754/4885SUV39H2 321/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | IKBKE 986/4885TBK1 3754/4885SUV39H2 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.